Search
Ruichu Medicine Secures Hundreds of Millions of Yuan in Series A Financing to Accelerate Clinical Translation of Anti-Aging Drugs
23 hour ago /
Read about 0 minute
Author：小编
Nanjing Ruichu Medicine Co., Ltd. has successfully completed an oversubscribed Series A financing round worth hundreds of millions of yuan, with investors including Cathay Capital, Fosun Health Capital, Yifeng Capital, and Huatai-GenScript. As the first innovative enterprise in China dedicated to targeting the biology of aging and developing senotherapeutics, Ruichu Medicine directly targets aging as a focal point for drug intervention. Through three major R&D platforms—eliminating, activating, and reprogramming senescent cells—the company has established a differentiated R&D pipeline covering multiple disease areas.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
